To probe this observation as a putative biomarker from a liquid biopsy perspective, as previously reported for IPMN [1], the concordance of KRAS mutations in circulating tumor DNA (ctDNA) and tumor tissue DNA was assessed by ddPCR in seven MCN with an available plasma specimen from Cohort 1 (Figure 1A). Here, KRAS is linked to neoplasm.